trial
as of 2026-07-01The Use of Galantamine HBr (Reminyl) in Electroconvulsive Therapy: Impact on Mood and Cognitive Functioning
NCTId NCT00566735
at a glance
Phase 3 · Completed
Enrollment 39 (actual)
Sponsored by Massachusetts General Hospital
Primary completion 2008-01
Synthesized from structured facts only — each point cited above.
Design & status
Phase
Phase 3
Status
Completed
Enrollment
39 (actual)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Triple
Start
2004-07
Primary completion
2008-01
Eligibility
ALL · 18 Years · 90 Years
Interventions & indications
Sponsors
Massachusetts General HospitalLead Sponsor
Ortho-McNeil Janssen Scientific Affairs, LLCCollaborator
Investigators
1
John D Matthews, MDPrincipal Investigator
Sites
1 total
Boston, United States
Linked catalysts
1
Facts & assertions
4 sourced
Enrollment
39
Phase
PHASE3
Primary Completion Date
2008-01
Status
COMPLETED
relationships
The graph out of here
drug
drug
lead_sponsor
collaborator
indication
investigator
person